MoonLake Immunotherapeutics

MLTX

As of the close on Sep 25, 2026

Price

$12.04

Market cap

—

The cover-page share count does not match the latest report's share count

P/E (diluted TTM)

—

Not meaningful: the last four quarters were a loss

EPS (TTM)

−$3.85

Four quarters to Jun 30, 2026

Dividend yield

—

Dividend records do not yet cover the latest payments

Figures shown here come from public SEC filings. Dates beside each section show the available history.

How MoonLake Immunotherapeutics Makes Money

No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.

Financial Summary

Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.

Loading financial history…

SEC filings supply these figures; updates after the dates shown are not included. This page includes 5 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 23, 2026.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Unusually large insider trades

Each trade is compared with the other insider trades of the same kind in the same security among MoonLake Immunotherapeutics's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.

2023-06-30 · Chen Bihua: Larger than 37 of the 38 other insider purchases of Class A Ordinary Shares on file. SEC filing
2023-03-20 · Chen Bihua: Larger than 36 of the 38 other insider purchases of Class A Ordinary Shares on file. SEC filing
2022-04-05 · Chen Bihua: Larger than all 38 other insider purchases of Class A Ordinary Shares on file. SEC filing

Independent insiders buying near the same time

2020-10-22–2020-10-22: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )

Purchases & sales (open market or private)

		Security	Code		Price	Filing
2026-06-22	Bodenstedt Matthias · Chief Financial Officer	Class A ordinary shares, par value $0.0001 per share	S — Open market or private sale	−39,120	22.04	SEC filing
2026-06-18	Bodenstedt Matthias · Chief Financial Officer	Class A ordinary shares, par value $0.0001 per share	S — Open market or private sale	−2,794	19.60	SEC filing
2026-06-17	Reich Kristian · Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	S — Open market or private sale	−50,000	19.43	SEC filing
2026-06-17	Bodenstedt Matthias · Chief Financial Officer	Class A ordinary shares, par value $0.0001 per share	S — Open market or private sale	−15,082	19.68	SEC filing
2026-06-16	Reich Kristian · Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	S — Open market or private sale	−50,000	18.70	SEC filing
2026-06-15	Reich Kristian · Chief Scientific Officer	Class A ordinary shares, par value $0.0001 per share	S — Open market or private sale	−50,000	18.89	SEC filing
2026-05-11	Bodenstedt Matthias · Chief Financial Officer	Class A ordinary shares, par value $0.0001 per share	S — Open market or private sale	−13,653	20.02	SEC filing
2026-04-14	Bodenstedt Matthias · Chief Financial Officer	Class A ordinary shares, par value $0.0001 per share	S — Open market or private sale	−2,426	19.56	SEC filing

Showing 8 of 20 rows

Grants, exercises, tax & gifts

		Security	Code		Filing
2026-06-17	Moukheibir Catherine · Director	Option to Buy	A — Grant, award, or other acquisition	+22,195	SEC filing
2026-06-17	Phillips Andrew John · Director	Option to Buy	A — Grant, award, or other acquisition	+22,195	SEC filing
2026-06-17	Loy Spike · Director	Option to Buy	A — Grant, award, or other acquisition	+22,195	SEC filing
2026-06-17	BIOTECHNOLOGY VALUE FUND L P · Director, 10% owner	Option to Buy	A — Grant, award, or other acquisition	+22,195	SEC filing
2026-06-17	Xavier Ramnik · Director	Option to Buy	A — Grant, award, or other acquisition	+22,195	SEC filing
2026-01-07	Bodenstedt Matthias · Chief Financial Officer	Class A ordinary shares, par value $0.0001 per share	A — Grant, award, or other acquisition	+354,296	SEC filing
2026-01-07	Santos da Silva Jorge · Chief Executive Officer	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+520,342	SEC filing
2026-01-07	Reich Kristian · Chief Scientific Officer	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+520,342	SEC filing

Showing 8 of 20 rows

Other activity

		Security	Code		Filing
2025-12-19	Santos da Silva Jorge · Chief Executive Officer	Class C ordinary shares, par value $0.0001 per share	D — Disposition to the issuer	−196,316	SEC filing
2025-12-19	Bodenstedt Matthias · Chief Financial Officer	Class C ordinary shares, par value $0.0001 per share	D — Disposition to the issuer	−294,473	SEC filing
2025-12-19	Reich Kristian · Chief Scientific Officer	Class C ordinary shares, par value $0.0001 per share	D — Disposition to the issuer	−35,389	SEC filing
2025-09-02	Reich Kristian · Chief Scientific Officer	Class C ordinary shares, par value $0.0001 per share	D — Disposition to the issuer	−48,978	SEC filing
2025-01-20	Reich Kristian · Chief Scientific Officer	Class C ordinary shares, par value $0.0001 per share	D — Disposition to the issuer	−111,949	SEC filing
2023-10-01	Sturge Simon · Director	Class C ordinary shares, par value $0.0001 per share	D — Disposition to the issuer	−342,980	SEC filing
2023-10-01	Santos da Silva Jorge · Chief Executive Officer	Class C ordinary shares, par value $0.0001 per share	D — Disposition to the issuer	−3,027,483	SEC filing
2023-10-01	Bodenstedt Matthias · Chief Financial Officer	Class C ordinary shares, par value $0.0001 per share	D — Disposition to the issuer	−62,972	SEC filing

Showing 8 of 10 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.